Alimera Sciences, Inc.
Investor Relations Department
6120 Windward Pkwy
Suite 290
Alpharetta, GA 30005
United States

Visit IR website
Sign-up for email alerts

NASDAQ: ALIM [1]	
Last Trade:	4.18
Trade Time:	4:00 PM ET May 17, 2013
Change:	-0.10 (2.336%)
Day Range	3.85 - 4.47
52-Week Range	1.26 - 5.10
Volume	229,200
Market Cap. ($M)	131.967
Shares Out (M)	31.571

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.

Alimera Sciences' advanced product candidate, ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies, and is going through the national phase in the approval process in Italy. Alimera Sciences is still seeking approval in the United States. The proposed treatment consists of a tiny, cylindrical polymide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid. Corticosteroids have a history of treating ocular diseases.

Alimera is committed to developing proactive solutions while remaining attuned to market needs and

Stock Performance

Press Releases [View all]

May 9, 2013
Alimera Sciences Reports First Quarter 2013 Financial Results

May 8, 2013
Alimera Sciences Secures $20 Million Debt Facility

May 7, 2013
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®

May 3, 2013
Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results

May 1, 2013
Alimera Sciences Announces New PDUFA Date For ILUVIEN®

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

First Quarter Financial Results

Mar 28, 2013
Annual Report (10-K)

Apr 29, 2013
Definitive Proxy Statement

May 10, 2013
Quarterly Report (10-Q)

Nov 7, 2012
Quarterly Report (10-Q)

opportunities. Learn more about Alimera with the shareholder tools below.

Learn More>>

… (more)

NASDAQ OMX